K2bio is a hybrid Contract Research Organization enabling early-stage life science companies to develop the next generation of innovative therapies. K2bio currently addresses the shortfall in lab space and vivarium facilities, and we provide process development, analytical development, and quality/regulatory support. We're working towards a $3,000,000 Series A-1 Preferred Stock financing round to fund an expansion into 9,000 SF of currently leased space to add a second vivarium and 5 privacy labs for tenants.
We have a hybrid delivery model
-Tenants – we provide office, lab and vivarium space to tenants, allowing them to perform their own research; also can provide services for them, giving them maximum technical leverage and financial flexibility
-Non-tenants – we can provide all the same services to companies who have office and lab space elsewhere
•This model is completely unique in the market and very well-received
•We intend to increase the capacity of our current offerings and ultimately expand our offerings to include cGMP manufacturing, which is also in great demand
Revenue Forecast:
2023: $5.1 million
2024: $10.9 million
2025: $15.3 million
2026: $18.2 million
Our Management Team:
Kieron Jones - Co-Founder and CEO:
•Former Director of Program Management & Commercial Development for Fujifilm Diosynth Biotechnologies Texas
•Former Operations Project Lead at Kalon prior to sale to Fujifilm
Andrew Strong - Co-Founder and Chairman:
•Founding CEO/President of Kalon; sold to Fujifilm in 2014
•Partner, Hogan Lovells US LLP
•Over 15 years of experience in CDMO/CRO industry
•Co-Chair of CPRIT’s Product Development Advisory Committee
Kevin Slawin, MD - Director:
•Founder and Managing Partner of Rapha Capital venture fund
•CEO of Ponce Therapeutics
•Founder of Bellicum Pharmaceuticals
•Board Member of multiple biotech startups
Gerard Fleury - Director:
•Former CFO of Paragon Bioservices / Catalent Gene Therapy
•Exec Team that sold Paragon to Catalent for $1.2B (2019)
•Previously C Level executive in and currently advisor to CDMO and biotech companies
Clifford Stocks - Director:
•Founder and CEO of OncoResponse, oncology biotech
•Built and managed ICOS CMO business sold to CMC Biologics
•Biotech executive in multiple startups with successful exits
Andrew DeSomma - Director:
•Founding member of Resolute Investments, LLC
•Two decades of Wall Street experience on sell side and buy side
Dan Clark, CPA, MBA - CFO:
•Seasoned financial expert with background in audit and management consulting
•Previously CFO of live biologic drug development company in Houston, TX
We have a full deck and term sheet available to serious prospective partners, and I'm really excited to meet with you.
Ready to Ask For Funding for your company?
Post a Funding Request